Cargando…

Analysis of Effectiveness, Safety, and Bleeding Related to Rivaroxaban in Elderly Patients

This study explored the efficacy and safety of rivaroxaban in elderly patients, at different doses and age of patients, and analyzed risk factors of bleeding. A retrospective analysis was conducted of 299 patients aged 60 years or older who were admitted to the First Hospital of Jilin University bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Huimin, Li, Ang, Zhang, Liping, Qin, Xiujiao, Jiang, Yanfang, Zhao, Huiying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370546/ https://www.ncbi.nlm.nih.gov/pubmed/32453608 http://dx.doi.org/10.1177/1076029620925923

Ejemplares similares

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series
por: Šimičević, Livija, et al.
Publicado: (2023)

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
por: Sherid, Muhammed, et al.
Publicado: (2016)

Non‐synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban
por: Zhao, Ming, et al.
Publicado: (2021)

Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta‐analysis
por: Jiang, Hongcheng, et al.
Publicado: (2021)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights
por: Gulilat, Markus, et al.
Publicado: (2021)

Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)
por: Song, Zi-Kai, et al.
Publicado: (2020)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Rivaroxaban: Bleeding from fungating breast cancer wound: case report
Publicado: (2021)

Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study
por: Xiang, Qian, et al.
Publicado: (2023)

Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
por: Chen, Xiehui, et al.
Publicado: (2021)

Increased cathepsin K levels in human atherosclerotic plaques are associated with plaque instability
por: Zhao, Huiying, et al.
Publicado: (2017)

Increased cathepsin K levels in human atherosclerotic plaques are associated with plaque instability
por: Zhao, Huiying, et al.
Publicado: (2018)

Rectus sheath hematoma and retroperitoneal bleeding due to rivaroxaban: a case report
por: Börekci, Elif
Publicado: (2019)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
por: Lai, Chao‐Lun, et al.
Publicado: (2017)

Non-hemorrhage-related adverse effects of rivaroxaban
por: Christopoulou, Eliza C., et al.
Publicado: (2017)

Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban‐treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding
por: Kline, Jeffrey A., et al.
Publicado: (2016)

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
por: Kubitza, Dagmar, et al.
Publicado: (2012)

A Cross‐Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies
por: Zhang, Liping, et al.
Publicado: (2017)

Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
por: Evans, Alison, et al.
Publicado: (2020)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
por: Kim, Hamin, et al.
Publicado: (2023)

Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?
por: Xavier, Flávia Dias, et al.
Publicado: (2016)

Rivaroxaban-Related Traumatic Large Subcutaneous Hematoma in the Calf Requiring Surgical Repair in an Elderly Patient
por: Tsujimoto, Yuki, et al.
Publicado: (2020)

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations
por: Ashton, Veronica, et al.
Publicado: (2020)

Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
por: Gruenebaum, Dane D., et al.
Publicado: (2014)

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
por: Patel, Manesh R., et al.
Publicado: (2018)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
por: Sennesael, Anne-Laure, et al.
Publicado: (2018)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
por: Chong, Jia, et al.
Publicado: (2020)

Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
por: Ansell, Jack, et al.
Publicado: (2021)

An exploratory study of effectiveness and safety of rivaroxaban in patients with left ventricular thrombus (R-DISSOLVE)
por: Yang, Qing, et al.
Publicado: (2023)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
por: Willmann, Stefan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e03cq6c4fc8r0r249apordo475